Talisman Metals (TLM) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
9 Jul, 2026Corporate overview and strategy
Focused on developing next-generation copper deposits in Morocco, leveraging a new mining code and strong local industry fundamentals.
Management team brings expertise in mineral exploration, mining entrepreneurship, finance, and Moroccan business operations.
Listed on AIM with management presence in Canada, providing access to multiple capital markets.
Share structure includes 64.2M shares outstanding, 3.1M options, and a 54% public float.
Strategic goal is to supply copper to meet growing global demand, especially for the energy transition.
Investment case: Morocco
Morocco is a premier mining destination with world-class geological potential and a reformed mining code since 2016.
Proximity to Europe and integration into global supply chains make it ideal for supplying critical raw materials.
Emerging as a hub for the battery industry, with supply agreements involving major automotive and battery companies.
Mining sector accounts for 30% of exports and employs 40,000 people; GDP in 2024 was $398bn.
Ranked #15 globally for investment attractiveness and #25 for policy perception by the Fraser Institute.
Project portfolio
Three main project areas: Tizert North/Fougnar, Tirzzit, and Argana, all targeting sediment-hosted copper deposits.
Tizert North/Fougnar projects are in the same basin as Managem's Tizert deposit (76Mt @ 0.8% Cu, 17g/t Ag).
Argana project targets copper, silver, and uranium in Triassic sandstones, with multiple mineralized showings.
Tirzzit project acquired from Aya Gold & Silver, with historic fieldwork revealing strong exploration targets.
Latest events from Talisman Metals
- Strategic pivot to copper exploration, €1.7m profit, and AIM readmission amid funding risks.TLM
H2 20256 Jul 2026 - Negative clinical results drove a €5.13m loss and a shift to cost control and new strategy.TLM
H2 202326 Feb 2026 - Exited biopharma after failed trials, pivoting to minerals exploration with improved 2024 results.TLM
H2 202426 Feb 2026 - H1 2025 saw a €1.24M loss, discontinued biopharma, and a shift to new business strategies.TLM
H1 202517 Feb 2026 - Losses narrowed and cash reserves remain, as strategic alternatives are actively pursued.TLM
H1 20246 Jan 2026